CLL Topics Banner: Therapies, Research and Patient Education for Chronic Lymphocytic Leukemia
CLL Topics Home Navigation Topics Alert Learning Tools About Us Feedback Feedback
Full Menu

Topics Alert

world balloon

Topics Alert Archive

Alert Number 29


Date: June 30, 2004

Berlex Labs is recruiting participants for their Phase-2 multi-center clinical trial, a combination of fludarabine and Campath for previously treated CLL patients.

We report on our participation in a Patient Advisory Board Meeting conducted by Berlex Laboratories, US distributors for Campath and fludarabine. FluCam 106 is a direct head-to-head comparison between Campath + fludarabine versus the better understood Rituxan + fludarabine therapy pioneered by Byrd, et. al. Campath + fludarabine is a powerful combination that has proven effective even in cases refractory to fludarabine and Campath as single agents. This is an important clinical trial, and we were fortunate to have an inside look at the way this trial is designed.

You can read about this in an article titled FluCam-106.

Be well,


NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.

Go to Alert Archive Listing

You may also retrieve a different Alert,
by entering a new Alert number here
(in the range 1 to 309)



Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.

Copyright Notice:

Copyright © 2002-2007 CLL Topics, Inc. All Rights Reserved.

All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.

However, you may download and print material from exclusively for your personal, noncommercial use.




up arrow